Limits...
Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma.

Li Q, Wang W, Machino Y, Yamada T, Kita K, Oshima M, Sekido Y, Tsuchiya M, Suzuki Y, Nan-Ya K, Iida S, Nakamura K, Iwakiri S, Itoi K, Yano S - Cancer Sci. (2014)

Bottom Line: BIW-8962 showed a significant antibody-dependent cellular cytotoxicity activity against the GM2-expressing MPM cell line MSTO-211H, the effect of which depended on the antibody concentration and effector/target ratio.Additionally, the GM2 expression was confirmed in the MPM clinical specimens.These data suggest that anti-GM2 antibodies may become a therapeutic option for MPM patients.

View Article: PubMed Central - PubMed

Affiliation: Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.

Show MeSH

Related in: MedlinePlus

Anti-GM2 antibody BIW-8962 showed therapeutic activity in an MSTO-211H orthotropic mouse model. MSTO-211H malignant pleural mesothelioma cells were inoculated into the thoracic cavity in SCID mice, and the animals were treated with BIW-8962 and/or human peripheral blood mononuclear cells (MNC). The mice were then i.v. administered BIW-8962 and/or MNC on days 7 and 14. At 3 weeks after tumor cell inoculation, the mice were sacrificed and their tumor weights were measured. The bars represent the mean of the group data. *P < 0.05 and **P < 0.01 between each treatment and the control groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317781&req=5

fig03: Anti-GM2 antibody BIW-8962 showed therapeutic activity in an MSTO-211H orthotropic mouse model. MSTO-211H malignant pleural mesothelioma cells were inoculated into the thoracic cavity in SCID mice, and the animals were treated with BIW-8962 and/or human peripheral blood mononuclear cells (MNC). The mice were then i.v. administered BIW-8962 and/or MNC on days 7 and 14. At 3 weeks after tumor cell inoculation, the mice were sacrificed and their tumor weights were measured. The bars represent the mean of the group data. *P < 0.05 and **P < 0.01 between each treatment and the control groups.

Mentions: The therapeutic efficacy of BIW-8962 was evaluated using an in vivo SCID mouse orthotropic model in which the animals were inoculated in the thoracic cavity with GM2-positive MSTO-211H cells and treated with BIW-8962 and/or human MNCs. BIW-8962 significantly decreased both the incidence and size of tumors (Fig.3, Table1). Notably, the concomitant administration of BIW-8962 and MNC had a greater effect on tumor incidence and size, whereas MNC injection alone showed weak antitumor activity. In addition, the incidence and volume of pleural effusion tended to be decreased by the co-administration of BIW-8962 and MNC.


Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma.

Li Q, Wang W, Machino Y, Yamada T, Kita K, Oshima M, Sekido Y, Tsuchiya M, Suzuki Y, Nan-Ya K, Iida S, Nakamura K, Iwakiri S, Itoi K, Yano S - Cancer Sci. (2014)

Anti-GM2 antibody BIW-8962 showed therapeutic activity in an MSTO-211H orthotropic mouse model. MSTO-211H malignant pleural mesothelioma cells were inoculated into the thoracic cavity in SCID mice, and the animals were treated with BIW-8962 and/or human peripheral blood mononuclear cells (MNC). The mice were then i.v. administered BIW-8962 and/or MNC on days 7 and 14. At 3 weeks after tumor cell inoculation, the mice were sacrificed and their tumor weights were measured. The bars represent the mean of the group data. *P < 0.05 and **P < 0.01 between each treatment and the control groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317781&req=5

fig03: Anti-GM2 antibody BIW-8962 showed therapeutic activity in an MSTO-211H orthotropic mouse model. MSTO-211H malignant pleural mesothelioma cells were inoculated into the thoracic cavity in SCID mice, and the animals were treated with BIW-8962 and/or human peripheral blood mononuclear cells (MNC). The mice were then i.v. administered BIW-8962 and/or MNC on days 7 and 14. At 3 weeks after tumor cell inoculation, the mice were sacrificed and their tumor weights were measured. The bars represent the mean of the group data. *P < 0.05 and **P < 0.01 between each treatment and the control groups.
Mentions: The therapeutic efficacy of BIW-8962 was evaluated using an in vivo SCID mouse orthotropic model in which the animals were inoculated in the thoracic cavity with GM2-positive MSTO-211H cells and treated with BIW-8962 and/or human MNCs. BIW-8962 significantly decreased both the incidence and size of tumors (Fig.3, Table1). Notably, the concomitant administration of BIW-8962 and MNC had a greater effect on tumor incidence and size, whereas MNC injection alone showed weak antitumor activity. In addition, the incidence and volume of pleural effusion tended to be decreased by the co-administration of BIW-8962 and MNC.

Bottom Line: BIW-8962 showed a significant antibody-dependent cellular cytotoxicity activity against the GM2-expressing MPM cell line MSTO-211H, the effect of which depended on the antibody concentration and effector/target ratio.Additionally, the GM2 expression was confirmed in the MPM clinical specimens.These data suggest that anti-GM2 antibodies may become a therapeutic option for MPM patients.

View Article: PubMed Central - PubMed

Affiliation: Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.

Show MeSH
Related in: MedlinePlus